Prelude Therapeutics, Inc.

Prelude Therapeutics Inc. is a clinical-stage precision oncology company. The Company is focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers. Its drug discovery engine is designed to identify biological targets and create new chemical entities (NCEs). Its pipeline includes six programs including methyltransferases, kinases, protein-protein interactions and targeted protein degraders. It is developing therapies in both solid tumors and hematological malignancies such as adenoid cystic carcinoma (ACC), homologous recombination deficient positive (HRD+), cancers, myelofibrosis (MF) and glioblastoma multiforme (GBM), amongst others. The Company’s product candidates include PRT543, PRT811, PRT1419, SMARCA2, PRT2527 and PRT-K4.